



RICK SNYDER  
GOVERNOR

STATE OF MICHIGAN  
DEPARTMENT OF HEALTH AND HUMAN SERVICES  
LANSING

NICK LYON  
DIRECTOR

October 2017

**Newborn Screening for Metabolic Disorders**  
**Removal of Short-chain acyl-CoA dehydrogenase deficiency and Isobutyryl-CoA dehydrogenase deficiency**

Dear Practitioner(s):

Following recommendations by the Michigan Newborn Screening Quality Assurance Advisory Committee (QAAC) and approval by the Legislature, two metabolic conditions have been removed from the newborn screening panel: **short-chain acyl-CoA dehydrogenase deficiency (SCAD)** and **isobutyryl-CoA dehydrogenase deficiency (IBD)**. This change was effective October 1, 2017.

In 2002, the American College of Medical Genetics determined the recommended uniform screening panel (RUSP) for newborn screening. SCAD and IBD were included as secondary targets, defined as conditions that could be identified while searching for a primary target. Although secondary targets did not meet all the criteria for inclusion as a primary target, their detection should constitute a clinically significant result leading to tangible benefits to the affected newborn, family, and society. In 2005, Michigan began screening for the 25 primary target diseases on the RUSP, along with SCAD, IBD, and other secondary target metabolic disorders identifiable by tandem mass spectrometry.

In 2016, a comprehensive review of patients identified with SCAD and IBD both in Michigan and reported in the literature revealed that these conditions appear to be largely benign. Additionally, other states and countries stopped screening newborns for these conditions.

After reviewing the available evidence, the Metabolic Quality Improvement Committee, comprised of a variety of specialists involved in treating patients with metabolic disorders, recommended removing SCAD and IBD from Michigan's panel because the identification of these conditions appears to have minimal to no clinical consequences. This recommendation was supported by the Technical Advisory Committee, responsible for providing expert review and input to the Newborn Screening Program, and ultimately by the QAAC, which is given the authority to remove disorders from the panel.

If you have clinical concerns relating to SCAD or IBD, Children's Hospital of Michigan Metabolic Center is available as a resource. The Center can be reached via phone at 313-832-9330.

MDHHS Newborn Screening staff are available to answer questions regarding this change. Please do not hesitate to contact us at 517-335-4181 or [newbornscreening@michigan.gov](mailto:newbornscreening@michigan.gov).

Sincerely,

A handwritten signature in cursive script that reads "Mary Kleyn".

Mary Kleyn, MSc  
Manager, Newborn Screening Follow-Up Program